I've watched labs with massive throughput opportunity, demand that would fill the sequencers they already own and justify the capital already spent, sit on the sidelines because the investment that would open up that throughput never gets funded. Not because the technology failed. Not because the lab can't execute. But because the accumulated weight of years of architectural decisions made the overhead per sample so high that scaling doesn't deliver acceptable ROI.
That's not a technology problem. It's a technical debt problem. And it compounds because the lab never stops changing. Every new assay, instrument, and payer rule lands on decisions made for a smaller, simpler lab, one defensible choice at a time, until you can't grow without rebuilding what you already have.
Here's the trap that catches even the most capable directors: the case for expansion almost always exists, and they still can't prove it. A lab's cost and workflow data lives in its operational systems. Its revenue, reimbursement, and outcomes live in billing. Nothing joins the two cleanly at the level of a single test, and where labs try, the join is brittle and partial. So a lab that would scale beautifully on capital it already owns can look, on a roll-up P&L, like it's simply bleeding money, and the new LIMS or automation line that would fix it reads as throwing good money after bad. The director isn't wrong about the opportunity. They just can't hand leadership a number they'll fund.
How technical debt accumulates
Laboratory technical debt doesn't announce itself. It accumulates quietly, one defensible decision at a time, over years. Each choice made sense in isolation. What turns them into debt is the rapid rate of change in a lab: it never stays at the volume, the menu, or the mix it was when the decision was made, and neither the systems nor the decisions baked into them keep pace. The cumulative effect is a lab that gets harder to operate just as you need it to scale. The four scenarios below are composited from real labs: different vendors, different modalities, same compounding mechanism.
The lab runs a mix of molecular work: routine PCR and syndromic panels alongside a growing NGS service. Leadership buys a single "comprehensive" LIMS to cover it all. Budget justification is clean: one vendor, one contract, one support relationship.
The platform handles the high-volume PCR menu fine. But the NGS workflow doesn't fit. Sample tracking is too rigid. Batch management doesn't support the flexibility NGS requires. Index assignment is clunky. Reporting templates can't handle the complexity of variant interpretation and re-classification.
So the lab hires a contractor to build the gap. Custom code bridges the workflow mismatch. It works. The contractor leaves.
Five years later: the lab needs to modify the workflow. The original code author is long gone. Little documentation exists, and the vendor won't support custom modifications: the exact code the lab paid to fill the product's gap. The lab owns the liability but not the knowledge to maintain it. And because the lab never stops evolving, every change becomes a professional-services line item it never budgeted for.
Lab buys a liquid handler that doesn't support API integration. Manual export to CSV is fine at the time: staff can upload the file to the LIMS without too much friction.
At 1,500 samples per year, manual export is tolerable. At 3,000 samples per year, data entry errors accumulate, staff burn out on repetitive manual tasks, and turnaround time slips. The bottleneck is now the thing that was supposed to automate the bottleneck.
The lab can't automate the handoff without replacing an instrument that still works perfectly well for the volume it was purchased to handle.
Lab implements an end-to-end workflow on a modern event-streaming backbone. The design is clean and well-defended in review: every system emits events, downstream systems subscribe, and the whole workflow becomes traceable.
The architecture works. What the lab didn't model: running this kind of platform reliably is its own engineering discipline. It requires a sustained level of in-house expertise to operate, evolve, and troubleshoot: expertise that has to be retained as people come and go.
Three years later: the IT lead who designed the system has moved on. The replacement IT team can keep things running but doesn't have the same depth. New workflows that used to take weeks now take months because nobody fully understands the existing design. Adding a new system means reverse-engineering decisions that were made years ago by people no longer at the lab. The architecture decision was right for a lab with sustained platform-engineering capacity. This lab didn't build that capacity until it was too late. The end-to-end workflow itself, and how to find the one step that's actually capping throughput, is its own piece.
Lab chooses on-premise deployment for the LIMS. Makes sense at 5,000 samples per year. Control, security, no ongoing cloud fees.
Now doing 15,000 samples per year. The OpEx for maintaining on-premise infrastructure (servers, backups, IT staff, security patches, disaster recovery) runs far higher than the lab ever put on paper, and much of it is avoidable overhead, not the irreducible cost of the workload. Worse: the sequencing platform could handle 3x current volume, but the infrastructure overhead makes scaling uneconomical. Expensive capital equipment running at less than half capacity.
Migration to cloud would require three months of revalidation and workflow downtime the lab can't afford. The lab is locked into the on-premise architecture, paying enterprise OpEx for a deployment model the volume no longer justifies.
Why it compounds invisibly
None of these decisions were wrong when they were made. The LIMS covered three modalities. The liquid handler automated a manual process. The event-streaming backbone made the workflow traceable end-to-end. The on-premise deployment gave the lab control. Each choice was rational. Each closed an immediate gap.
But they were made in isolation, without modeling how they would interact with future growth, future systems, or future operational reality. The debt compounds when these decisions stack on top of each other, creating a workflow that's brittle, expensive to maintain, and impossible to modify without breaking something else.
Recognizing these decisions as accumulated compromises is its own discipline, and the subject of a companion piece. This article is about the harder problem that follows: once you can see the debt, why it stays so hard to fund.
Two failure modes show up over and over. Together they explain why labs that look fine on the operational dashboard can be one event away from a serious problem.
Single points of failure in the workflow
The custom code is a problem. The bigger problem is that the custom code, and in some cases entire systems in the end-to-end workflow, depends on a single individual. When that person leaves, there is no cross-training, no contingency plan, and often no backfill ready to take on the work.
The pattern is recognizable: the senior tech who is the only one who knows how the LIS interface actually works. The bioinformatician who wrote all the analysis scripts with no documentation and no version control. The IT contractor who configured the middleware, left two years ago, and produced no handoff documentation. The lab manager who manually reconciles LIS/LIMS discrepancies every morning on tribal knowledge alone.
One person quits. The critical workflow breaks. The lab scrambles to hire a replacement, can't onboard the new hire without the original employee's knowledge, and ends up paying outside consultants to reverse-engineer what the previous employee built. Then the cycle repeats with the next hire. This isn't a staffing problem. It's a knowledge management problem. Labs that don't document systems, cross-train staff, and build redundancy into critical workflow steps are one resignation letter away from operational crisis.
Underutilized capital equipment
The most expensive outcome of all: high-throughput platforms sitting underutilized because the infrastructure around them can't support the volume the equipment was designed to handle. Labs that invested heavily in sequencing capacity running well below half capacity, not because demand doesn't exist, but because the overhead per sample makes growth uneconomical.
The utilization number is what everyone sees. The OpEx trajectory if the lab tries to grow is what everyone sees. The conclusion writes itself: the lab isn't a growth investment. The capital sits idle while demand routes elsewhere. The longer this lasts, the harder it is to make the case for the modernization that would put that capacity to work.
The path out
The most expensive thing a lab can do is accept the status quo. The way out isn't a single project or a single vendor; it's a deliberate, multi-year effort to reduce brittleness, build redundancy, and regain operational control. It starts with a frank assessment of where you actually stand, and what the status quo is quietly costing you. Look under the rug and see things as they are, and the next steps get much clearer.
Inventory the systems and decisions that compound your operational risk. Which systems are dependent on a single person? What custom code exists, who wrote it, and is it documented? What equipment can't integrate with newer systems? What vendor contracts constrain your options? What architectural decisions are costing you OpEx every month? And map the boundaries: what each system is actually the source of truth for, and where that ownership blurs. Where two systems both claim the same data, or none clearly owns it, is where the debt hides. Then baseline the numbers alongside them: your current unit economics and operational performance. What does each test actually cost and earn? Where do utilization and throughput really sit, and where does turnaround slip? Seeing boundaries, risks, and economics together tells you which constraints cost the most, so you spend effort where it moves the needle. A structured readiness assessment runs the systems-and-boundaries side of this across every domain.
Not all technical debt is equal. Some constraints hurt more than others. Ask: what breaks first if a key person quits tomorrow? What constraint keeps you from scaling? What costs you the most in ongoing professional services? Fix the highest-pain item first, not the easiest one. Easy wins don't compound; expensive constraints do.
Fixing technical debt isn't free, and it isn't fast. Documenting undocumented systems takes time. Cross-training staff takes time. Migrating from on-premise to cloud requires validation downtime. Replacing equipment means capital expense. Short-term pain is the price of long-term stability. Labs that refuse to endure it stay locked in the pattern indefinitely.
Every system comes with some technical debt; there's no such thing as one that doesn't. The goal is to take on less of it, and to design for the lab you're becoming, not the one you are today. Choose platforms with documented APIs over proprietary interfaces. Invest in cloud-first infrastructure where it makes operational sense. Negotiate for vendor handoff documentation in implementation contracts where you have the leverage. Document everything. Cross-train everyone.
Nobody funds infrastructure modernization just because it makes operations easier. It gets funded when you can show the ROI, and that starts with quantifying what technical debt is costing you right now. Translate the audit into a sequenced, business-cased roadmap that frames remediation as asset-utilization recovery and OpEx reduction, not as a maintenance project.
Who pays for technical debt
Laboratory technical debt creates costs for almost everyone with a stake in the lab's success. The lab leader pays in operational burden, manual workarounds, single points of failure, increased professional services fees, inefficient infrastructure, and staff burnout from doing work that should be automated. The lab itself pays in reduced agility, the inability to adopt new technologies without breaking existing workflows, and underutilized capital equipment that should have already paid for itself. The vendor pays too, even when it doesn't realize it: delayed onboarding, missed launch targets, support resources tied up maintaining custom configurations rather than building new product capability.
The common thread is a dependency nobody chose: a system that should operate independently but can't, so the lab keeps paying outside help to keep it running. If that's where your lab is, the question worth asking is straightforward: is this the outcome you wanted when you bought the platform?
It usually isn't. Not because anyone acted in bad faith, but because it's the sum of decisions nobody made on purpose, that everybody now lives with. The path out doesn't start with another vendor selection. It starts with the structured audit of what you've already accumulated, and the discipline to fix the highest-pain item first.
The number that should decide the whole thing is the one no one is set up to build. The data lives in two systems that were never built to meet. That's the gap Fulcrix closes: it joins your operational and financial data into workflow-level economics, so the audit becomes a board-ready number instead of a maintenance ask. It doesn't fix the debt; it makes the case to fix it fundable.
See Fulcrix → · Next: find your binding constraint → · Take the free Lab Readiness Quick-Check →
Founder, HelixWrks. Twelve years across the molecular workflow, most recently as a product leader at a leading sequencing company, where I owned, by discipline:
- Product strategy & management: the lab-software stack upstream of the sequencer
- LIMS & lab automation: the systems that run the bench
- Integration & connectivity: LIS, EHR/EMR, and middleware, upstream and downstream of the sequencer
- Workflow strategy: the end-to-end genomics workflow, not a single step
Vendor-neutral: no referral fees, no implementation revenue.